SAFETY AND EFFECTIVENESS OF ATLAVAC AVIAN VACCINES

SAFETY AND EFFICIENCY OF ATLAVAC AVIAN VACCINES



SAFETY AND EFFECTIVENESS OF ATLAVAC AVIAN VACCINES

ATLAS VETERINAIRE has developed a range of avian vaccines consisting of:
ATLAVAC HB1: live Hitchner B1 strain against Newcastle disease;
ATLAVAC ND: inactivated vaccine based on the LaSota strain, against Newcastle disease;
ATLAVAC GUMBORO: live vaccine based on the intermediate Lukert strain against Gumboro disease;
ATLAVAC GUMBORO PLUS: live vaccine based on the intermediate Lukert strain plus;
ATLAVAC H120: live vaccine based on the Massachussets serotype, strain H120 against infectious bronchitis.



The clinical trials on the Moroccan field were carried out under the real conditions of the veterinary practices, according to the vaccination programs adapted to the broiler by the veterinarians supervising concerned farms and in three different regions of Morocco.

The objectives set by these studies were to evaluate the safety and efficacy of ATLAVAC vaccines. For this, two groups of tests have been set up:


A / CLINICAL TRIALS OF VACCINES ATLAVAC GUMBORO and ATLAVAC GUMBORO PLUS

Field clinical trials were conducted in:
farm A located in the region of Marrakech, with a capacity of 7000 chickens per building and
farm B located in the region of Casablanca, with a capacity of 8800 chickens per building.

The evaluated parameters were:
Clinical signs and possible side effects (Gumboro lesions), kinetics of antibodies against Gumboro disease, and zootechnical performance (mortality rate, body weight, indices of consumption).

Experimental protocol

The animals on each of the two farms A and B are separated into 2 groups:
Group I (ATLAVAC): concerns all animals in the 1st building that have been vaccinated with both ATLAVAC GUMBORO and ATLAVAC GUMBORO PLUS vaccines
Group II (vaccinated witness): includes animals from the 2nd building that have been vaccinated with other similar vaccines already marketed in Morocco and used by the farmer of each farm according to his usual schedule.

Both ATLAVAC GUMBORO and ATLAVAC GUMBORO PLUS vaccines were administered in the drinking water at the dose recommended by the manufacturer.

The follow-up of the clinical trials was carried out as follows:
Follow-up of clinical signs of Gumboro disease throughout the duration of breeding for both groups and on both farms.
Tracking of Gumboro's disease lesions by autopsy of dead animals every week between the 2nd and 6th week of age and whenever abnormal mortality is observed.
Tracking of Gumboro's disease antibody (ELISA) titres on blood samples taken at 1 day, 35 days and 42 days of age.
Monitoring zootechnical performance indicators during the whole breeding period (body weight, mortality rate, consumption index).

Results and Interpretations
Evaluation of the safety of ATLAVAC GUMBORO and ATLAVAC GUMBORO PLUS vaccines:
Both groups (ATLAVAC), both at farm A and at farm B, up to 4 weeks of age, did not show clinical signs or particular lesions that could be attributed to administration of ATLAVAC GUMBORO and ATLAVAC GUMBORO PLUS vaccines.

b) Evaluation of the efficacy of ATLAVAC GUMBORO and GUMBORO PLUS vaccines (Farm A):

At farm A, the efficacy of ATLAVAC vaccines was demonstrated by: the absence of clinical signs and necropsy lesions suggestive of Gumboro disease, the mortality rate that was normal throughout the rearing period and the serological titres were homogeneous and high enough / vaccinated control group. All this is in favor of a good protection of animals vaccinated with ATLAVAC vaccines. On the other hand, the zootechnical performance indices show a slight advantage when the group vaccinated with the ATLAVAC GUMBORO and ATLAVAC GUMBORO PLUS vaccines compared to the control group vaccinated with similar commercial vaccines.

c) Evaluation of the efficacy of ATLAVAC GUMBORO and GUMBORO PLUS vaccines (Farm B):

During the 6 weeks, no suspicion of Gumboro disease was found in the group vaccinated with ATLAVAC vaccines. The vaccinated control group showed a slight shift in Gumboro disease marked by a higher mortality rate and higher and somewhat heterogeneous antibody titres with hypertrophy of the Fabricius bursal in some cases at autopsy.

The zootechnical performance indicators show a slight advantage of the group vaccinated with ATLAVAC GUMBORO and ATLAVAC GUMBORO PLUS vaccines, compared to the control group vaccinated with similar commercial .

B / CLINICAL TRIALS OF VACCINES ATLAVAC HB1, ATLAVAC H120 and ATLAVAC ND

They were made on farms C and D in the Tiflet region.

Farm C had a capacity of 12,000 chickens per building and

Farm D capacity 22,550 chickens per building.

The evaluated parameters are:

clinical signs, possible side effects (lesions / ND and BI), antibody kinetics against Newcastle Disease and zootechnical performance (mortality rate, body weight, Consumption Index (CI)).

Experimental Protocol:

The animals of each of 2 farms C and D are separated into 2 groups:
Group I (ATLAVAC): applies to all animals in the first building that have been vaccinated with the three vaccines ATLAVAC HB1, ATLAVAC H120 and ATLAVAC ND.
Group II (vaccinated witness): concerns the animals of the 2nd building which have been vaccinated by other similar vaccines of the trade and used by the breeder according to its usual program.

The two live vaccines ATLAVAC HB1 and ATLAVAC H120 were administered by hatch fogging at the first day of age and at the dose recommended by the manufacturer. ATLAVAC ND inactivated vaccine was given by IM injection at the 7th day of age.

The follow-up of the clinical trials was carried out as follows:
Follow-up of the clinical signs of the 2 diseases (ND and BI) throughout the duration of the breeding for the 2 groups and the 2 farms.
Follow-up of lesions of both diseases (ND and BI) by autopsy of dead animals every 10 days and whenever an abnormal and observed mortality.
Follow-up of antibody titres by IHA, on blood samples taken at 21 days, 35 days and 42 days of age.
Monitoring zootechnical performance indicators throughout the breeding period (Mortality rate, body weight, consumption index).

Results and Interpretations
Evaluation of the safety of the ATLAVAC H120, ATLAVAC HB1 and ATLAVAC ND vaccines

Both groups (ATLAVAC) at both farm C and farm level D, up to 4 weeks of age, did not show clinical signs or particular lesions that could be attributed to administration of ATLAVAC H120, ATLAVAC HB1 and ATLAVAC ND vaccines.
Evaluation of the efficacy of the ATLAVAC H120, ATLAVAC HB1 and ATLAVAC ND vaccines.



The efficacy of the ATLAVAC H120, ATLAVAC HB1 and ATLAVAC ND vaccines is confirmed by the absence of clinical signs and specific lesions of Newcastle disease and Infectious Bronchitis throughout the duration of the trial. Serological titres higher in IHA in the group vaccinated with ATLAVAC vaccines are also indicators of this effectiveness. They are significantly higher than those vaccinated with similar vaccines on the market.

The zootechnical performance indices show a slight advantage for the group vaccinated with ATLAVAC vaccines.

GENERAL CONCLUSIONS:

At the end of the 4 field trials conducted in 4 different broiler breedings, and in 3 different regions of Morocco, we can conclude that ATLAVAC GUMBORO, ATLAVAC GUMBORO PLUS, ATLAVAC H120, ATLAVAC BH1 and ATLAVAC ND vaccines:
All have been shown to be completely safe for broilers from different farms and in different parts of Morocco.
Are effective and provide good protection against Gumboro Disease, Newcastle Disease and Infectious Bronchitis.
The zootechnical performances obtained in groups vaccinated with ATLAVAC vaccines are relatively better compared to control groups vaccinated with similar vaccines on the market.


Please download the report in full